CyPep-1 is an innovative, first-in-class, tumor membrane targeting immunotherapy. CyPep-1 activates an immune response against cancer cells and increases the effect from other immunotherapies like Immune Checkpoint Inhibitors (ICI) (e.g. anti-PD-1). In this project we will develop and validate PreCyse, a predictive biomarker profile that can identify patients that will benefit from treatment with CyPep-1. PreCyse aims to demonstrate that a prognostic biomarker can enable delivery of personalised therapy in cancer, and that this improves clinical outcomes. The biomarker profile will be implemented in the late-stage clinical- and commercial development of CyPep-1.
In this project we will develop and validate PreCyse, a predictive biomarker profile that can identify patients that will benefit from treatment with CyPep-1. This biomarker profile will be used for the identification of highly responsive patients and will be crucial for the successful late-stage clinical development of CyPep-1. The project will characterise the molecular mode of action of CyPep-1 and downstream signalling events in different tumor genotypes in order to define biomarkers that identify tumour types responsive to treatment with CyPep-1. The project will include patient populations responding to CyPep-1 monotherapy and in combination with PD-1 inhibitor (Pembrolizumab).
PLEASE SEE ATTACHED EUROSTARS APPLICATION FOR MORE INFORMATION.